Search
mifamurtide (Mepact)
Approved in Europe. Not FDA-approved in US.
Granted orphan drug status by the FDA in 2001
Denied approval by the FDA in 2007
Indication:
- osteosarcoma, post surgical resection
Dosage:
- liposomal infusion
Adverse effects:
- fever (~90%)
- vomiting, fatigue and tachycardia (~50%)
- infections, anemia, anorexia, headache, diarrhea, constipation (>10%)
Mechanism of action:
- synthetic dipeptide derivative that binds NOD2
General
antineoplastic agent (chemotherapeutic agent)
Database Correlations
PUBCHEM correlations